Full text is available at the source.
Abstract
Lipid nanoparticles (LNPs) are the leading delivery platform for nucleic acid therapeutics due to their high encapsulation efficiency and scalable manufacturing.
- Poly(ethylene glycol)-lipids (PEG-lipids) enhance steric stabilization and size control but also introduce limitations such as complement activation and anti-PEG antibodies.
- Accelerated blood clearance associated with PEGylation constrains repeated and long-term dosing strategies for LNPs.
- Recent advances in LNP designs include non-PEG polymers, zwitterionic lipids, polypeptides, and modified PEG analogues.
- The properties of LNPs, including formation, biodistribution, and cellular uptake, are influenced by factors such as polymer chemistry and grafting architecture.
- Challenges remain in the clinical application of PEG-free and PEG-modified LNPs, highlighting the need for further research into their in vivo behavior.
Simplified